IVX 037
Alternative Names: IVX-037Latest Information Update: 28 Sep 2024
Price :
$50 *
At a glance
- Originator ImmVirX
- Class Antineoplastics; Immunotherapies; Oncolytic viruses
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Solid tumours
- Preclinical Colorectal cancer; Liver cancer
Most Recent Events
- 06 Sep 2024 Preclinical trials in Colorectal cancer in Australia (IV), prior to September 2024 (ImmVirx pipeline, September 2024)
- 06 Sep 2024 Preclinical trials in Liver cancer in Australia (IV), prior to September 2024 (ImmVirx pipeline, September 2024)
- 06 Sep 2024 ImmVirx announces intention to submit IND to US FDA for Solid tumours in the US, in 2024 ((ImmVirx pipeline, September 2024)